This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
P

ASCO® 2024 Insights: "NETTER-2 Study - Efficacy and Safety of 177Lu-DOTA-TATE in Newly Diagnosed Advanced Grade 2/3 Gastroenteropancreatic NETs"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Philip Philip
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Philip Philip
0 views
July 8, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

2024 ASCO® Annual Meeting Insights Hub: GI Videos

12:27
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreat…

Feat. J. Knox
12:29
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Fruquintinib in Refractory mCRC"

Feat. C. Eng
11:57
COR2ED The Heart of Medical Education

ASCO® 2024 Summary: "Latest Practice-Changing Data in Breast Ca…

Feat. M. Socinski, P. R. Galle, S. Dawood, E. Smyth, S. Klempner
View All

Recommended

AUTOPLAY
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
24:56
Florida Gastroenterologic Society

Neuroendocrine Tumors in the GI Tract

Feat. A. Luthra
15:20
Integrity CE

Sequencing Systemic Treatments for Well-Differentiated NETs

Feat. J. Strosberg
06:03
Total Health

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Feat. A. Grothey
13:06
Yale Cancer Center

NETs 101 and Overview of Medical Management

Feat. P. Kunz
05:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "212Pb-DOTAMTATE, a Targeted Alpha Therapy…

Feat. J. Strosberg
15:24
Horizon CME

MRD in GI Malignancies: Current Clinical Utility of ctDNA

Feat. A. Scott
13:47
Oncology Data Advisor

New Developments in Neuroendocrine Tumor Treatment

Feat. S. Kareff, A. Chauhan
16:31
Integrity CE

Debates in NET Treatment: Surgery vs. IR for Liver-Limited Disease

Feat. E. Liu
27:34
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Medical Oncology Updates in NETs

Feat. P. Kunz
19:29
Integrity CE

Metastatic Grade 2 NET: Case Presentation and Panel Discussion

Feat. A. De Jesus-Acosta, L. Bjork Solnes, J. Strosberg, E. Liu, R. Lidell
20:30
Total Health

Neuroendocrine Cancers: Background, Diagnosis, and Current Treatment

Feat. R. Lentz
22:31
2023 Johns Hopkins Updates in Gastrointestinal Cancers

Controversies in Management of Neuroendocrine Tumors

Feat. T. Pawlik
11:41
Northwell Health

Neuroendocrine Cancers of the Lung

Feat. N. Seetharamu
12:23
Integrity CE

2L Therapy for Metastatic NET: Case Presentation and Panel Discussion

Feat. A. De Jesus-Acosta, L. Bjork Solnes, J. Strosberg, E. Liu, R. Lidell
09:59
Insights from 2024 ESMO Sarcoma and Rare Cancers Congress

Lurbinectedin + Irinotecan in Pre-Treated Gastroenteropancreatic Neu…

Feat. R. Garcia-Carbonero
51:13
Yale Cancer Center

The Second Century in the Land of Neuroendocrine Tumors

Feat. J. Yao
02:49
ecancer

ESMO 2023 Insights: "Alliance A021602 Study - Cabozantinib vs. …

Feat. J. Chan
37:15
Total Health

Practical Considerations in the Management of Advanced Neuroendocrin…

Feat. J. Del Rivero